Therapy Areas: Oncology
Lytix reports phase II results showing durable responses in advanced melanoma
21 April 2026 - Clinical-stage biotech company Lytix Biopharma ASA (Euronext Growth Oslo:LYTIX) on Tuesday reported final Phase II results for ruxotemitide (LTX-315) in combination with pembrolizumab ...
Rznomics reports RZ-001 interim clinical data in hepatocellular carcinoma at AACR 2026
21 April 2026 - Rznomics Inc, a clinical-stage biopharmaceutical company based in South Korea, announced on Monday the presentation of interim clinical data from its ongoing study of RZ-001, an RNA ed...
Akeso presents positive Phase II results from cadonilimab combination study at AACR 2026
21 April 2026 - Chinese pharmaceutical company Akeso Inc (HK:9926) announced on Monday that positive Phase II results from the COMPASSION-26 study evaluating cadonilimab, its first-in-class PD-1/CTLA-...
GSK secures China approval for Blenrep in relapsed multiple myeloma
20 April 2026 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) declared on Monday that it has received approval from China's National Medical Products Administration for Blenrep (belant...
Accent Therapeutics presents ATX-295 data at AACR Annual Meeting 2026
20 April 2026 - Clinical-stage biopharmaceutical company Accent Therapeutics on Friday presented preclinical data supporting its potentially best-in-class KIF18A inhibitor, ATX-295, at the American As...
10x Genomics introduces new in situ spatial biology platform
20 April 2026 - Life science technology company 10x Genomics Inc (Nasdaq:TXG) on Saturday introduced Atera, an in situ spatial biology platform designed to deliver whole-transcriptome spatial analysis...